한국어
Quantus

P&K Skin Research Center

347740 · KOSDAQ
₩1,813-1.04%
2026-09-04 close

P&K Skin Research Center last closed at ₩1,813 (-1.04%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C+
Overall: 건강관리 180/291 · top 62%
Factor composite · relative position in sector

PER 9.35 · PBR 0.71 — own-history percentile 100/100 · 100/100

Open self-history band
PER100/100
PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2022: 38원20222023: 35원2024: 30원2025: 40원40원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
C+
Growth
B-
Yield
B-
Safety
B+
Reference indicatorView observed cut rates

Paid 4 consecutive years · Raised 1 consecutive years · Yield 2.21% (based on 2025 payment of 40원) · 3-year growth +2.2%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 21.55
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
21.55
Beneish M-Score
-2.74

No statistical flag

Sloan accrual
-3.92%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +20.2% 성장하면서 영업이익률이 9.3%에서 14.5%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +20.2%영업이익률 9.3%→14.5%FCF 9,654

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 212 of 287, share 0%.

212 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6피엔케이피부임상연구센타0%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
14.5%
Interest coverage
97.5x
Return on equity (ROE)
7.6%

Operating margin −5pp

Tolerable
Interest coverageBase 97.5x adverse case 63.8x
Return on equity (ROE)Base 7.6% adverse case 2.2%

Revenue −15%

Tolerable
Interest coverageBase 97.5x adverse case 82.8x
Return on equity (ROE)Base 7.6% adverse case 2.8%

Interest rate +2pp

Tolerable
Interest coverageBase 97.5x adverse case 20.1x
Return on equity (ROE)Base 7.6% adverse case 3.2%

Interest coverage limit

Current margin 14.3pp

Interest coverage limit at an operating margin of 0.1%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

P&K Skin Research Center's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About P&K Skin Research Center
What technical signals does P&K Skin Research Center (347740) have?
P&K Skin Research Center current technical signals: no active technical signal.
Is P&K Skin Research Center a cup-and-handle pattern?
No. P&K Skin Research Center has no valid cup-and-handle signal right now.
What are P&K Skin Research Center's financials and valuation?
P&K Skin Research Center's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy